State of the art of mobile health technologies use in clinical arrhythmia care.

The rapid growth in consumer-facing mobile and sensor technologies has created tremendous opportunities for patient-driven personalized health management. The diagnosis and management of cardiac arrhythmias are particularly well suited to benefit from these easily accessible consumer health technologies. In particular, smartphone-based and wrist-worn wearable electrocardiogram (ECG) and photoplethysmography (PPG) technology can facilitate relatively inexpensive, long-term rhythm monitoring.

Management of Persistent Left Superior Vena Cava: Overcoming Lead and Vascular Complications With Transcatheter Pacing System Implantation.

Isolated persistent left superior vena cava (PLSVC) is a rare congenital anomaly typically found incidentally due to its asymptomatic nature. However, it can present technical challenges for device implanters. We report a case involving a patient with PLSVC, for whom the implantation of a transcatheter pacing system proved to be the most effective long-term solution.

Update in atrial fibrillation.

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with major morbidity and mortality. Atrial enlargement, remodeling, and fibrosis are key to initiation and perpetuation of AF. Therapy for AF is directed at symptom control via rate or rhythm control, as well as prevention of thromboembolic events.

Ventricular tachycardia as a presentation of congenital left ventricular aneurysm.

Left ventricular aneurysm (LVA) describes a region of ventricular wall that is thinner than the adjacent myocardial segments, balloons outward and exhibits either akinesis or dyskinesis. Congenital LVA is diagnosed by exclusion with a very low incidence, especially in adult patients with very few cases reported. Clinically, most congenital LVA are asymptomatic.

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.

Sudden cardiac death (SCD) is the most common cause of death among patients with heart failure and left ventricular systolic dysfunction. Implantable cardioverter-defibrillators (ICDs) have been shown to be the single most effective therapy for primary prevention of SCD in patients with heart failure. The superiority of this therapy was clearly established for patients with ischemic cardiomyopathy by large clinical trials, such as the Multicenter Automatic Defibrillator Implantation Trial (MADIT), Multicenter Unsustained Tachycardia Trial (MUSTT), and MADIT-II studies.

Survey of cardiac rhythm management and device implant patterns in Puerto Rico: analysis of 13,854 cardiac implants.

Background: Surveys of cardiac pacing and implantable cardiovertor defibrillators (ICD) have been reported since 1969 and 1993 respectively. Increasing costs of medical technology, budget constraints and emergent new clinical indications prompted our committee to conduct the first survey of cardiac rhythm management and device implant patterns in Puerto Rico.

Method: Clinical and demographic data were obtained for all cardiac devices sold and implanted from 2000 to 2006, through a joint agreement with official representatives of the 2 largest manufacturers and distributors of cardiac pacemakers and ICD in Puerto Rico.